Johnson Johnson Aktie WKN: 853260 / ISIN: US4781601046
Symbol: JNJ

131,06EUR
+3,86EUR
+3,03%
05.03.2021
156,10USD
+3,08USD
+2,01%
06.03.2021
Diese Aktie kaufen
mehr Daten anzeigen
Werbung

Johnson Johnson Aktien News

06.03.21
Janssen Announces 96-week Results of Phase 3b Study Demonstrating the Continued Safety and Efficacy of Long-acting HIV Treatment of Rilpivirine and Cabotegravir (EN, Johnson & Johnson)
05.03.21
Johnson & Johnson COVID-19 Vaccine Granted Authorization under Interim Order by Health Canada For Emergency Use (EN, Johnson & Johnson)
02.03.21
Johnson & Johnson Statement on Collaboration with Merck (EN, Johnson & Johnson)
28.02.21
Johnson & Johnson Announces U.S. CDC Advisory Committee Recommends First Single-Shot COVID-19 Vaccine for Adults 18 and Older in U.S. (EN, Johnson & Johnson)
28.02.21
Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use (EN, Johnson & Johnson)
26.02.21
Johnson & Johnson Single-Shot COVID-19 Vaccine Candidate Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee (EN, Johnson & Johnson)
19.02.21
Johnson & Johnson Announces Submission to World Health Organization for Emergency Use Listing of Investigational Single-Shot Janssen COVID-19 Vaccine Candidate (EN, Johnson & Johnson)
16.02.21
Johnson & Johnson Announces Submission of European Conditional Marketing Authorisation Application to the EMA for its Investigational Single-Shot Janssen COVID-19 Vaccine Candidate (EN, Johnson & Johnson)
08.02.21
Janssen Announces Treatment with ERLEADA® (apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer (EN, Johnson & Johnson)
08.02.21
Janssen Presents Results from Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA® (apalutamide) and ZYTIGA® (abiraterone acetate) Combination (EN, Johnson & Johnson)
08.02.21
SPRAVATO® (Esketamine Nasal Spray) Authorised in Europe for the Rapid Reduction of Depressive Symptoms in a Psychiatric Emergency for Patients with Major Depressive Disorder (EN, Johnson & Johnson)
05.02.21
Johnson & Johnson to Participate in the Cowen 41st Annual Health Care Virtual Conference (EN, Johnson & Johnson)
04.02.21
Johnson & Johnson Announces Submission of Application to the U.S. FDA for Emergency Use Authorization of its Investigational Single-Shot Janssen COVID-19 Vaccine Candidate (EN, Johnson & Johnson)
03.02.21
REVEAL Lite 2 Risk Calculator Offers Simplified Model to Assess One-Year Mortality Risk Status in Patients with Pulmonary Arterial Hypertension (PAH) (EN, Johnson & Johnson)
03.02.21
Johnson & Johnson to Participate in the Raymond James 42nd Annual Institutional Investors Conference (EN, Johnson & Johnson)
02.02.21
Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU (EN, Johnson & Johnson)
29.01.21
Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial (EN, Johnson & Johnson)
27.01.21
Johnson & Johnson to Participate in the Citi's 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference (EN, Johnson & Johnson)
26.01.21
Johnson & Johnson Reports 2020 Fourth-Quarter and Full Year Results (EN, Johnson & Johnson)
22.01.21
Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir), the First Long-Acting Regimen for the Treatment of HIV (EN, Johnson & Johnson)
21.01.21
Auris Health Announces Publication of Results from BENEFIT Study of MONARCH® Platform in CHEST (EN, Johnson & Johnson)
19.01.21
DePuy Synthes Receives 510(k) FDA Clearance for VELYS™ Robotic-Assisted Solution Designed for Use with the ATTUNE® Total Knee System (EN, Johnson & Johnson)
16.01.21
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis (EN, Johnson & Johnson)
14.01.21
Johnson & Johnson Statement on Political Contributions (EN, Johnson & Johnson)
13.01.21
Johnson & Johnson COVID-19 Vaccine Candidate Interim Phase 1/2a Data Published in New England Journal of Medicine (EN, Johnson & Johnson)
13.01.21
Janssen to Highlight Commitment to Lung Cancer Science and Innovation with Eight Data Presentations at the International Association for the Study of Lung Cancer’s 2020 World Conference on Lung Cancer (EN, Johnson & Johnson)
07.01.21
Statement by Alex Gorsky, Johnson & Johnson Chairman and CEO (EN, Johnson & Johnson)
04.01.21
Johnson & Johnson Announces Quarterly Dividend for First Quarter 2021 (EN, Johnson & Johnson)
18.12.20
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results (EN, Johnson & Johnson)
14.12.20
Johnson & Johnson to Participate in the 39th Annual J.P. Morgan Healthcare Conference (EN, Johnson & Johnson)
06.12.20
New Data Demonstrate Long-Term Benefit of IMBRUVICA® (ibrutinib) as First-Line Treatment for High-Risk Chronic Lymphocytic Leukemia (EN, Johnson & Johnson)
05.12.20
Janssen Presents First Data from the Phase 1 Study of the GPRC5DxCD3 Bispecific Talquetamab in Patients with Relapsed or Refractory Multiple Myeloma (EN, Johnson & Johnson)
05.12.20
Updated Results from the Phase 1 Study of the BCMAxCD3 Bispecific Teclistamab Show Preliminary Efficacy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma (EN, Johnson & Johnson)
05.12.20
Disease-Free Survival Data from CAPTIVATE Study Demonstrate Benefit of IMBRUVICA® (ibrutinib)-Based Regimen as Fixed Duration, First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (EN, Johnson & Johnson)
03.12.20
Janssen Submits Application to U.S. FDA Seeking Approval of Amivantamab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations (EN, Johnson & Johnson)
03.12.20
Johnson & Johnson Names Dr. Nadja West, retired United States Army lieutenant general and former United States Army Surgeon General to its Board of Directors (EN, Johnson & Johnson)
17.11.20
Johnson & Johnson to Address Racial and Social Injustice Through Platform that Aims to Eliminate Health Inequities for People of Color (EN, Johnson & Johnson)
16.11.20
Johnson & Johnson Initiates Second Global Phase 3 Clinical Trial of its Janssen COVID-19 Vaccine Candidate (EN, Johnson & Johnson)
14.11.20
Johnson & Johnson and U.S. Department of Health & Human Services Expand Agreement to Support Next Phase of COVID-19 Vaccine Candidate Research and Development (EN, Johnson & Johnson)
10.11.20
New XARELTO® (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020 (EN, Johnson & Johnson)
Seite: 123

Johnson Johnson News

Johnson Johnson News: auf dieser Seite finden Sie alle Johnson Johnson News und Nachrichten zur Johnson Johnson Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Johnson Johnson News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Johnson Johnson News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.
Werbung

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln